The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-2576PMID 19706811
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599.

  2009cited by this paper
• Reply to V. Van Belle et al

  2009cited by this paper
• VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts).

  2009cited by this paper
• Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599.

  2009cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

  2008cited by this paper
• Association of polymorphisms of angiogenesis genes with breast cancer

  2008cited by this paper
• Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

  2008cited by this paper
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

  2008cited by this paper
• Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736).

  2008cited by this paper
• Association of polymorphisms of angiogenesis genes with breast cancer

  2008cited by this paper
• VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

  2008cited by this paper
• Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

  2008cited by this paper
• Drug Insight: VEGF as a therapeutic target for breast cancer

  2007cited by this paper
• Association of Vascular Endothelial Growth Factor Gene Polymorphism with Myocardial Infarction in Patients with Type 2 Diabetes

  2007cited by this paper
• Gender-specific association of the VEGF -2578C > A polymorphism in Korean patients with colon cancer.

  2007cited by this paper
• Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients.

  2007cited by this paper
• Investigation of Vascular Endothelial Growth Factor Gene Polymorphisms and Its Association with Clinicopathologic Characteristics in Gastric Cancer

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer

  2007cited by this paper
• Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

  2007cited by this paper
• Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

  2007cited by this paper
• Functional Vascular Endothelial Growth Factor −634G>C SNP Is Associated With Proliferative Diabetic Retinopathy

  2007cited by this paper
• Association of VEGF-1499C-->T polymorphism with diabetic nephropathy in type 1 diabetes mellitus.

  2007cited by this paper
• Large-Scale Evaluation of Candidate Genes Identifies Associations between VEGF Polymorphisms and Bladder Cancer Risk

  2007cited by this paper
• Multiple Variants in Vascular Endothelial Growth Factor (VEGFA) Are Risk Factors for Time to Severe Retinopathy in Type 1 Diabetes

  2007cited by this paper
• Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer.

  2007cited by this paper
• Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes

  2006cited by this paper
• Genetic Polymorphisms of Vascular Endothelial Growth Factor and Angiopoietin 2 in Retinopathy of Prematurity

  2006cited by this paper
• Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males.

  2006cited by this paper
• Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women.

  2006cited by this paper
• Genetic Polymorphism of Vascular Endothelial Growth Factor: Impact on Progression of IgA Nephropathy

  2006cited by this paper
• Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia.

  2006cited by this paper
• Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome.

  2006cited by this paper
• Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

  2006cited by this paper
• Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy.

  2006cited by this paper
• Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival

  2006cited by this paper
• Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

  2005cited by this paper
• Angiogenesis in life, disease and medicine

  2005cited by this paper
• VEGF polymorphisms and severity of atherosclerosis

  2005cited by this paper
• Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.

  2005cited by this paper
• VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5.

  2005cited by this paper
• Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes.

  2004cited by this paper
• A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated pbm cells

  2003cited by this paper
• VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death

  2003cited by this paper
• Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter.

  2003cited by this paper
• A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk

  2003cited by this paper
• Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus.

  2003cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

  2003cited by this paper
• Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection.

  2002cited by this paper
• Role of genetic polymorphisms in tumour angiogenesis

  2002cited by this paper
• A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.

  2002cited by this paper
• Influence of cytokine gene polymorphisms on the development of prostate cancer.

  2002cited by this paper
• New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation.

  2001cited by this paper
• A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels

  2000cited by this paper
• Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene.

  1999cited by this paper
• Tumor induction of VEGF promoter activity in stromal cells.

  1998cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper

• Combination of Anti-Angiogenics and Immunotherapies in Renal Cell Carcinoma Show Their Limits: Targeting Fibrosis to Break through the Glass Ceiling?

  2024cites this paper
• Impact of VEGFA promoter polymorphisms on esophageal cancer risk in North-West Indians: a case-control study

  2022cites this paper
• VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

  2022cites this paper
• Association between Common Variants in VEGFA Gene and the Susceptibility of Primary Knee Osteoarthritis

  2022cites this paper
• Investigation of the effect of vascular endothelial growth factor gene 936 C/T polymorphism in familial Mediterranean fever patients

  2022cites this paper
• Association of specific single nucleotide variants (SNVs) in the promoter and 3'-Untranslated region of Vascular Endothelial growth factor (VEGF) gene with risk and higher tumour grade of head and neck cancers.

  2021cites this paper
• Strong and Significant Associations of Single Nucleotide Variants (SNVs) in the Promoter and 3'-Untranslated Region (3'-UTR) of Vascular Endothelial Growth Factor (VEGF) Gene with Head and Neck Cancers

  2021cites this paper
• Correlation of gene polymorphisms of vascular endothelial growth factor with grade and prognosis of lung cancer

  2020cites this paper
• Vascular endothelial growth factor as a potential marker of subclinical organ damage mediated by arterial hypertension

  2019cites this paper
• Association between VEGFA gene polymorphisms and bleeding complications in patients maintaining therapeutic international normalized ratio.

  2019cites this paper
• Association between HNF4A mutations and bleeding complications in patients with stable international normalized ratio.

  2019cites this paper
• Single‐nucleotide polymorphisms of VEGF‐A and VEGFR‐2 genes and risk of infantile hemangioma

  2018cites this paper
• Multidisciplinary Management of Rectal Cancer

  2018cites this paper
• Should Biological Targeted Agents be Combined with Preoperative Chemoradiation in Rectal Cancer? An Update

  2018cites this paper
• A SRSF1 self-binding mechanism restrains Mir505-3p from inhibiting proliferation of neural tumor cell lines

  2018cites this paper
• Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients

  2017cites this paper
• Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab

  2017cites this paper
• Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review.

  2017cites this paper
• Cancer Drug Delivery: Pharmacogenetics, Biomarkers, and Targeted Therapies

  2017cites this paper
• Therapeutic Implications of Angiogenesis in Cancer

  2017cites this paper
• Resistance to Angiokinase Inhibitors

  2016cites this paper
• A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

  2016cites this paper
• The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma

  2016cites this paper
• ارتباط پلیمورفیسم ژن VEGF +405C/G با سرطان پستان در شمال ایران

  2016cites this paper
• Resistance to Tyrosine Kinase Inhibitors

  2016cites this paper
• Association of VEGF gene +405C/G polymorphism with the risk of breast cancer in northern Iran

  2016cites this paper
• Associations between VEGF polymorphisms and risk of psoriasis : a case-control study in a Chinese Han population and meta-analysis

  2016cites this paper
• Novel Candidate Biomarkers of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma: A Systematic Review

  2016cites this paper
• Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer

  2015cites this paper
• Vascular endothelial growth factor polymorphisms as effect modifiers of oral squamous cell carcinoma risk: A systematic review and meta-analysis.

  2015cites this paper
• Transcriptional regulation of the VEGF gene in dependence of individual genomic variations.

  2015cites this paper
• A Vascular Endothelial Growth Factor Gene Polymorphism Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasm

  2015cites this paper
• Role of vascular endothelial growth factor in non‑small cell lung cancer pathogenesis.

  2015cites this paper
• Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.

  2015cites this paper
• Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma.

  2015cites this paper
• Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?

  2015cites this paper
• Investigating the association of vascular endothelial growth factor polymorphisms with breast cancer: a Moroccan case–control study

  2014cites this paper
• Effects of obesity on vascular endothelial growth factor and erythropoietin in patients with arterial hypertension

  2014cites this paper
• Antiangiogenic therapy: Patient selection and clinical outcomes

  2014cites this paper
• Clinical Toxicity Profile of VEGF Inhibitors

  2014cites this paper
• What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?

  2014cites this paper
• Prevalence of +405G>C,−1154G>A Vascular Endothelial Growth Factor Polymorphism in Breast Cancer

  2013cites this paper
• An In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoction, Erxian Decoction, on Human Ovarian Cancer Models

  2013cites this paper
• Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel

  2013cites this paper
• VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.

  2013cites this paper
• Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma.

  2013cites this paper
• Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.

  2013cites this paper
• Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.

  2013cites this paper
• Targeted therapy for brain tumours: role of PARP inhibitors.

  2012cites this paper
• Clinical imaging of tumor angiogenesis.

  2012cites this paper
• Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment.

  2012cites this paper
• The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer

  2012cites this paper
• VEGF -634C/G Genotype is Predictive of Long-term Survival after Treatment with a Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma

  2012cites this paper
• The effect of CCND1 +870A>G and VEGF +936C>T polymorphisms on oral cancer development and disease-free survival in a Taiwan population.

  2012cites this paper
• Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

  2012cites this paper
• Predictive value of loci in VEGF pathway genes in bevacizumab treatment.

  2012cites this paper
• Mechanisms of resistance to vascular endothelial growth factor blockade

  2012cites this paper
• Target-based anti-angiogenic therapy in breast cancer.

  2012cites this paper
• Predictive Factors of Efficacy of Sunitinib Therapy in Gastrointestinal Stromal Tumours

  2012cites this paper
• Angiogenesis in endometriosis: the role of circulating angiogenic cells and the endometrium

  2012cites this paper
• The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study

  2012cites this paper
• Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals.

  2011cites this paper
• Angiogenic Activity of the Peritoneal Mesothelium: Implications for Peritoneal Dialysis

  2011cites this paper
• Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.

  2011cites this paper
• Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer.

  2011cites this paper
• Progress in Peritoneal Dialysis

  2011cites this paper
• The angiogenic process as a therapeutic target in cancer.

  2011cites this paper
• Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

  2011cites this paper
• Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy

  2011cites this paper
• Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

  2011cites this paper
• Biomarkers in Tumor Angiogeneis and Anti-Angiogenic Therapy

  2011cites this paper
• Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?

  2011cites this paper
• Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

  2011cites this paper
• Molecular Predictors of Response to Antiangiogenesis Therapies

  2011cites this paper
• Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors.

  2010cites this paper
• Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.

  2010cites this paper
• CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration

  2010cites this paper
• Biomarkers of angiogenesis and their role in clinical oncology

  2010cites this paper
• evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review

  2010cites this paper
• Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.

  2010cites this paper
• The Prognostic Value of Haplotypes in the Vascular Endothelial Growth Factor A Gene in Colorectal Cancer

  2010cites this paper
• Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises

  2010cites this paper
• evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review

  2010cites this paper
• The Vascular Endothelial Growth Factor-2549 Insertion/Deletion Polymorphism Is Not Associated with Susceptibility to Hepatocellular Carcinoma in Chinese

  2010cites this paper
• Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinoma.

  2010cites this paper
• The long road to colorectal cancer therapy: searching for the right signals.

  2010cites this paper
• Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma

  2010cites this paper
• Antiangiogenic therapies in early-stage breast cancer.

  2010cites this paper
• [Recent developments of pharmacogenomics in the treatment of colorectal cancers].

  2010cites this paper